Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco Animal Health (NYSE: ELAN) has appointed Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma, currently Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, brings extensive experience in biopharmaceutical development and manufacturing. She previously held leadership positions at Sana Biotechnology and Genentech/Roche. Dr. Ma was recognized as one of the 'Top 20 Women Leaders in Biopharma R&D' by Endpoints News in 2020 and is a Fellow of the American Institute for Medical and Biological Engineering. Her expertise will support Elanco's Innovation, Portfolio and Productivity strategy and development of next-generation pipeline products.
Elanco Animal Health (NYSE: ELAN) reported Q3 2024 revenue of $1,030 million, with 1% organic constant currency growth. The company posted reported net income of $364 million and adjusted net income of $66 million. Adjusted EBITDA was $163 million (15.8% of revenue), with reported EPS of $0.73 and adjusted EPS of $0.13.
The company recorded a pre-tax gain of $640 million from July 2024 aqua business divestiture and tightened its full-year 2024 guidance to revenue of $4,420-4,450 million. Notable achievements include U.S. FDA approvals for Zenrelia and Credelio Quattro. For 2025, Elanco expects mid-single-digit organic revenue growth, with adjusted EBITDA growth in low single digits.
At the recent Reuters Transform Food & Agriculture event, 200 industry leaders discussed key requirements for transforming the future of food. The focus areas included: supply chain integration, developing scalable and profitable innovations for farmers, and maintaining a growth mindset. Katie Cook, VP of Livestock Sustainability and U.S. Farm Animal Marketing, moderated a panel with representatives from various agricultural companies, discussing supply chain collaborations and innovations. A fireside chat with Jackie Klippenstein from Dairy Farmers of America addressed initiatives for reducing and measuring enteric methane emissions, particularly focusing on Scope 3 emissions reductions.
Elanco Animal Health Incorporated (NYSE: ELAN) has announced the date for its third quarter 2024 financial results. The company will release its results on Thursday, November 7, 2024, followed by a conference call with the investment community and media at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through a link that will be posted on Elanco's investor relations website. A replay of the call will also be made available on the website shortly after its conclusion.
Elanco Animal Health's CEO, Jeff Simmons, discusses a climate solution for the dairy and meat industry in a Fast Company article. He highlights that cattle can be part of addressing global hunger and climate issues. The FDA recently approved Bovaer® (3-NOP), Elanco's methane-reducing feed ingredient for lactating dairy cattle. This product can lower methane emissions by around 30%, equivalent to 1.2 metric tons of CO2e emissions annually per cow.
Simmons emphasizes the importance of climate neutral farming and introduces tools like UpLook for measuring greenhouse gas emissions and Athian's carbon insetting marketplace. These innovations aim to help farmers reduce, measure, and monetize emission reductions, benefiting the entire food chain. The goal is to achieve climate neutral livestock farms within this decade, making U.S. farmers more competitive while helping food companies meet their emissions goals.
Elanco Animal Health (NYSE: ELAN) has received FDA approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the broadest canine oral parasiticide, offering protection against six parasites: fleas, ticks, heartworms, roundworms, hookworms, and tapeworms. This product is the first to combine four active ingredients in a single, monthly chewable tablet for dogs aged eight weeks and older. Credelio Quattro starts killing ticks and fleas within 4 hours, achieving over 99% flea kill within 8 hours and 100% within the first day, remaining effective for a month. It provides 100% protection against heartworm disease from the first dose and is effective against zoonotic parasites, which can infect both pets and humans. Elanco plans to launch Credelio Quattro in Q1 2025, joining its existing portfolio of parasiticides, including Seresto® and Advantage®.
Elanco Animal Health (NYSE: ELAN) announced FDA approval and launch of Zenrelia™ (ilunocitinib tablets), a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis. Zenrelia enters the estimated $1.7 billion global canine dermatology market, offering an effective solution for controlling pruritus in dogs at least 12 months old.
In a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor, with 77% of Zenrelia-treated dogs achieving clinical remission of itch, compared to 53% treated with Apoquel®. Zenrelia's launch price is about 20% less for nearly all dogs compared to the current JAK inhibitor, making it more affordable for pet owners.
The approval represents Elanco's first entry into the fast-growing canine dermatology market, expanding their comprehensive portfolio for veterinarians.
Elanco recently explored the challenges and motivations of veterinarians through interviews with Dr. Emily Swiniarski and Dr. Amanda Schnitker. The discussion highlighted the complex reality of veterinary medicine, where professionals enter the field for their love of animals but find their work heavily involves managing pet owners' emotions and expectations. Key issues facing veterinarians include:
1. Ongoing impacts of the COVID-19 pandemic
2. Compassion fatigue
3. Shortage of veterinarians and technical staff
4. Visit decline due to new competitive care models
Despite these challenges, veterinarians find fulfillment in providing care and connecting with animals and their owners. Elanco supports veterinarians by offering business expertise and innovative solutions for unmet needs in animal health.
Elanco Animal Health (NYSE: ELAN) has provided an update on its contract manufacturing partner, TriRx Speke , which has entered into trading administration in the UK. Elanco has a long-term supply agreement with TriRx for select farm animal products. The company is working with administrators to ensure business continuity and explore options. Elanco expects minimal supply disruption in 2024 and is underwriting operational costs to maintain production and employee payments in the interim.
Despite an anticipated reduction of $5 million to $10 million in adjusted EBITDA for 2024 due to the TriRx situation, Elanco maintains its full-year adjusted EBITDA guidance of $900 million to $940 million.
Elanco Animal Health (NYSE: ELAN) announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference, scheduled for September 4-5, 2024. The company's President and CEO Jeff Simmons, along with Executive VP and CFO Todd Young, will engage in a fireside chat on Thursday, September 5 at 3:20 p.m. ET.
Investors and interested parties can access a live audio webcast of the session through the "Events and Presentations" section of Elanco's investor website. For those unable to attend live, a replay will be available for approximately 30 days after the event. This conference participation highlights Elanco's commitment to investor relations and provides an opportunity for stakeholders to gain insights into the company's strategies and performance.